Business Wire - Research and Markets: Benchmark Schering-Ploughs Performance against Key Rivals In The Ethical Pharmaceutical Sector
DUBLIN, Ireland — Research and Markets (http://www.researchandmarkets.com/reports/c43905) has announced the addition of Schering-Plough: PharmaVitae Profile to their offering.
This analysis examines the historical and forecast performance for Schering-Plough in the ethical pharma sector. The profile encompasses global company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.
Reasons to order your copy:
* Benchmark Schering-Ploughs performance against key rivals in the ethical pharmaceutical sector
Related Results
WALL STREET CHOICE: SCHERING-PLOUGH SHOWS PROMISE
Marlborough, Mass., Firm’s Allergy Drug Is Turned Away by FDA.
Manufacturing Problems Cast Pall on Schering-Plough Earnings.(Statistical Dat…
Tab for Allergy Pills Likely to Rise.
New Jersey Insurers’ Changed Policy on Allergy Drugs Presents New Irritant.
* Evaluate how Schering-Plough has utilized a focused externalization strategy to drive sales growth out to 2011
* Evaluate the consequences of the company’s reliance on its core product portfolio, with the late-stage R&D pipeline underperforming
Some Products mentioned include:
* Clarinex
* Claritin
* Elocon
* Garenoxacin
* Garenoxacin
* Golimumab
* Intron
* Nasonex
* Nasonex/Asmanex/Elocon (AIID)
* Noxafil
* Remicade
* Sarasar
* Temodar
* Vytorin
* Zetia
Content Outline:
Chapter 1
Executive summary
Chapter 2
Corporate history
Chapter 3
Historical performance
Chapter 4
Forecast performance
Chapter 5
Key products and competitors
Chapter 6
Appendix
IMS vs. company-reported data reconciliation
Abbreviations
List of Tables
List of Figures
For more information visit http://www.researchandmarkets.com/reports/c43905
Source: Datamonitor
COPYRIGHT 2006 Business Wire
COPYRIGHT 2008 Gale, Cengage Learning
